Literature DB >> 2825666

Degradation of type I collagen films by mouse osteoblasts is stimulated by 1,25 dihydroxyvitamin D3 and inhibited by human recombinant TIMP (tissue inhibitor of metalloproteinases).

B M Thomson1, S J Atkinson, J J Reynolds, M C Meikle.   

Abstract

Mouse calvarial osteoblasts grown on native type I collagen films degrade collagen in response to 1,25 (OH) 2vitD3. Collagen degradation is accompanied by increased latent collagenase and gelatinase secretion and by a reduction in free TIMP. Exogenous human recombinant TIMP abolished 1,25 (OH) 2vitD3 stimulated collagen degradation and inhibited background collagenolysis. No active metalloproteinases were detectable in the culture medium suggesting sequestration of active enzyme at the site of action or inhibition by residual TIMP. Chondrocytes could not mimic osteoblasts in this system.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2825666     DOI: 10.1016/0006-291x(87)90918-1

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  Human osteoblasts in vitro secrete tissue inhibitor of metalloproteinases and gelatinase but not interstitial collagenase as major cellular products.

Authors:  L Rifas; L R Halstead; W A Peck; L V Avioli; H G Welgus
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

2.  The effect of lipopolysaccharide from bacteroides gingivalis and muramyl dipeptide on osteoblast collagenase release.

Authors:  H J Sismey-Durrant; S J Atkinson; R M Hopps; J K Heath
Journal:  Calcif Tissue Int       Date:  1989-05       Impact factor: 4.333

3.  Inhibition of bone resorption in vitro by selective inhibitors of gelatinase and collagenase.

Authors:  P A Hill; A J Docherty; K M Bottomley; J P O'Connell; J R Morphy; J J Reynolds; M C Meikle
Journal:  Biochem J       Date:  1995-05-15       Impact factor: 3.857

4.  Dexamethasone enhances vitamin D-24-hydroxylase expression in osteoblastic (UMR-106) and renal (LLC-PK1) cells treated with 1alpha,25-dihydroxyvitamin D3.

Authors:  Izuru Kurahashi; Ayako Matsunuma; Tetsuya Kawane; Masatoshi Abe; Noboru Horiuchi
Journal:  Endocrine       Date:  2002-03       Impact factor: 3.925

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.